Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:human_immunoglobulin_G
|
| gptkbp:approvalYear |
2007
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J06BA02
|
| gptkbp:contraindication |
IgA deficiency with antibodies against IgA
history of anaphylactic reaction to immunoglobulin |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
gptkb:water
solution for infusion |
| gptkbp:halfLife |
about 36 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Privigen
|
| gptkbp:indication |
replacement therapy in primary humoral immunodeficiency
treatment of chronic immune thrombocytopenic purpura |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:CSL_Behring
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea fatigue headache chills |
| gptkbp:storage |
2-25°C
|
| gptkbp:usedFor |
gptkb:chronic_immune_thrombocytopenic_purpura
immunodeficiency |
| gptkbp:bfsParent |
gptkb:CSL_Limited
|
| gptkbp:bfsLayer |
6
|